Administration of gene-based vaccines prohibited, and penalty provided.

2025-2026 Regular Session Introduced by Pam Altendorf and 4 co-sponsors

Prohibits administering gene-based vaccines in Minnesota and imposes penalties for violations.

Authors added Altendorf and Roach

Purpose and Intent

HF 3152 seeks to prohibit the administration of gene-based vaccines within Minnesota and establishes penalties for violations. The bill is framed as prohibiting a specific category of vaccines (gene-based) from being administered in the state, with consequences for individuals or entities that administer them in violation of the act.

Key Provisions

Prohibition on Administration

The bill prohibits administering gene-based vaccines in Minnesota. The exact definition of “gene-based vaccines” is not included in the information provided, but it typically would refer to vaccines using gene-delivery technologies (e.g., mRNA, viral vectors) to instruct cells to produce an antigen.

Penalties

The legislation includes a penalty structure for violations. Specifics (e.g., fines, penalties per instance, injunctive relief, or civil penalties) are not detailed in the provided summary, but the bill “provides penalties” for administering gene-based vaccines in violation of the act.

Scope and Enforcement

The act is state-level and would apply to administration within Minnesota. It may designate enforcement mechanisms, responsible agencies, and potential exemptions or defenses, though those details are not provided here.

What Would Be Affected

Healthcare Providers

Physicians, nurses, pharmacists, clinics, hospitals, and other entities that administer vaccines would be directly impacted if they engage in administering gene-based vaccines within Minnesota.

Patients

Individuals receiving vaccines in the state could be affected insofar as gene-based vaccines would be prohibited; access restrictions could apply.

Vaccine Manufacturers and Suppliers

Entities that supply gene-based vaccines to Minnesota providers could be affected indirectly if the prohibition restricts administration.

Procedural and Timeline Aspects

Introduction and Referral

Introduced and read for the first time on April 7, 2025. Referred to the Health Finance and Policy committee for consideration.

Additions to Authors

On April 10, 2025, Altendorf and Roach were added as authors (co-sponsors appear to include Walter Hudson, Shane Mekeland, Pam Altendorf, Drew Roach, and John Burkel).

Next Steps

As a bill introduced and referred to committee, it would require committee hearings, potential amendments, floor votes in the House, and then further steps in the legislative process (e.g., Senate consideration) to become law. Specific timelines would depend on the committee schedule and session rules.

Notes and Considerations

Definitions and Exceptions: The summary does not provide the statutory definitions of “gene-based vaccines” or any potential exemptions (e.g., compassionate use, clinical trials, emergency authorizations, or public health exemptions). These elements are critical for understanding the bill’s practical effect.

Penalty Details: The exact nature and amount of penalties are not specified in the information provided. The severity of penalties will influence compliance and enforcement.

Public Health Implications: Prohibiting gene-based vaccines could have broad implications for vaccine development, patient choice, and public health strategies in Minnesota, depending on the availability and efficacy of non-gene-based alternatives.

If you’d like, I can extract more precise details (definitions, exemptions, enforcement mechanisms, and penalty amounts) once the bill’s text or committee analyses are available.

Bill